Screener
Cytokinetics CYTK Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of convertible and long-term debt | 27,358 | 41,181 |
| Derivative liabilities measured at fair value | 30,700 | 31,100 |
| Deferred revenue | 1,653 | 1,612 |
| Other current liabilities | 3,304 | 3,833 |
| Total current liabilities | 181,429 | 202,452 |
| Term loans, net | 248,202 | 246,384 |
| Convertible notes, net | 871,527 | 869,597 |
| Liabilities related to revenue participation right purchase agreements, net | 558,054 | 520,559 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's accrued expenses?
- Cytokinetics (CYTK) reported accrued expenses of $3.3M in Q2 2026.
- How has Cytokinetics's accrued expenses changed year-over-year?
- Cytokinetics's accrued expenses decreased by 65.6% year-over-year, from $9.59M to $3.3M.
- What is the long-term trend for Cytokinetics's accrued expenses?
- Over 5 years (2020 to 2025), Cytokinetics's accrued expenses has grown at a 29.6% compound annual growth rate (CAGR), from $1.05M to $3.83M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Cytokinetics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude